← Back to Evidence Atlas
E2 ModerateHigher confidencePEM ✓Reviewed
Standard · 3 min

Incidence and Prevalence of Post-COVID-19 Myalgic Encephalomyelitis: A Report from the Observational RECOVER-Adult Study.

Vernon, Suzanne D, Zheng, Tianyu, Do, Hyungrok et al. · Journal of general internal medicine · 2025 · DOI

Quick Summary

This study tracked over 11,000 people who had COVID-19 and about 1,400 who didn't, following them for at least 6 months to see how many developed ME/CFS. Researchers found that people who had COVID-19 were nearly 5 times more likely to develop ME/CFS compared to people who never had COVID-19. About 4.5% of COVID-infected participants developed ME/CFS, compared to only 0.6% of uninfected people.

Why It Matters

This is the first large-scale study to quantify how often ME/CFS develops specifically after COVID-19, providing critical epidemiological data that validates ME/CFS as a documented post-infection complication. These findings support the need for ME/CFS recognition, screening protocols, and clinical management guidelines in post-COVID care, while also advancing understanding of infection-triggered ME/CFS mechanisms.

Observed Findings

  • ME/CFS incidence was 2.66 per 100 person-years in SARS-CoV-2 infected participants compared to 0.93 in uninfected controls (hazard ratio 4.93).
  • 4.5% of COVID-infected participants (531/11,785) met ME/CFS diagnostic criteria versus 0.6% of uninfected participants (9/1,439).
  • Post-exertional malaise was the most common ME/CFS symptom, occurring in 24.0% (2,830/11,785) of infected participants.
  • 88.7% of participants with post-COVID-19 ME/CFS (471/531) also met RECOVER criteria for long COVID.

Inferred Conclusions

  • SARS-CoV-2 infection significantly increases the risk of developing ME/CFS, with infected individuals nearly 5 times more likely to develop the condition than uninfected controls.
  • ME/CFS is a diagnosable and measurable sequela of COVID-19, distinct from but frequently overlapping with broader long COVID presentations.
  • Post-exertional malaise represents a key clinical feature of post-COVID-19 ME/CFS and should be a focus of clinical screening and management.

Remaining Questions

  • What underlying biological mechanisms (viral persistence, immune dysfunction, mitochondrial dysfunction, etc.) drive the development of post-COVID-19 ME/CFS?
  • Why do some infected individuals develop ME/CFS while others don't, and are there identifiable risk factors (genetic, immunological, viral variants) that predict susceptibility?
  • How do symptom trajectories differ between post-COVID-19 ME/CFS and ME/CFS occurring after other infections, and does treatment response differ?
  • Can objective biomarkers be identified to confirm ME/CFS diagnosis and replace reliance on self-reported symptoms?

What This Study Does Not Prove

This study does not establish what biological mechanisms cause post-COVID-19 ME/CFS, nor does it determine whether all cases are identical or involve different pathways. The reliance on self-reported symptoms means some mild cases may go undetected while borderline cases could be misclassified, and symptom fluctuation over time could affect prevalence estimates.

Topics

Post-Exertional Malaise

Tags

Method Flag:PEM_DEFINED

Metadata

DOI
10.1007/s11606-024-09290-9
PMID
39804551
Review status
Editor reviewed
Evidence level
Single-study or moderate support from human research
Last updated
7 April 2026